Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRIO Bladder: Durvalumab and Tremelimumab with Radiation in Bladder Cancer
NCT04073160Phase 1Withdrawn
- Start
- Jun 2020
- Primary completion
- Jul 2021
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 1
01
Overview
Phase 1, open-label trial of durvalumab and tremelimumab in Urothelial Bladder Cancer (UBC). Planned start Jun 2020; status: withdrawn.
02
Drugs
durvalumabtremelimumab
03
Conditions
Urothelial Bladder Cancer (UBC)
Beyond the preview
Go deeper on NCT04073160.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04073160.